Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Ribozyme closes $48mm private financing

13 Jun 2003

Executive Summary

Ribozyme Pharmaceuticals (nucleic acid technologies) closed a $48mm private financing of 145.45mm common shares priced at $0.33 each (a 22% premium to market average) and five-year warrants to buy 30mm more common shares at $0.42. Investors (and their post-offering stakes in the company) are Sprout Group (41.8%), Venrock Associates (18.9%), Oxford Bioscience (14.2%), Techno Venture Management (9.2%), and Granite Global Ventures (fund sponsored by Venrock, Singapore Economic Development Board, and U.S. Bancorp Piper Jaffray) (3.7%).
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By